SPOTLIGHT: Deal or no deal for Lilly?


Remember the expert witness who leaked damaging documents about Zyprexa, Eli Lilly's schizophrenia med? He agreed to pay $100,000 to settle Lilly's lawsuit against him. But now the two are fighting over Lilly's' announcement of the deal because the company said he admitted breaking the law, but his lawyer says he admitted no such thing. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.